. Author manuscript; available in PMC: 2012 Aug 13.

Published in final edited form as: Biosens Bioelectron. 2007 Dec 14;23(10):1413–1421. doi: 10.1016/j.bios.2007.11.022

Table 1.

The number (and percentage in that sample group) of serum samples with antibodies to the citrullinated peptide (CitPept) or the negative control peptide (nonCitPept), by the three different assays (nanotube, ELISA and microarray). The serum groups are rheumatoid arthritis (RA), normal control (NC) and osteoarthritis (OA).

		RA (n = 32)		NC (n = 13)		OA (n = 11)
Nanotube	CitPept	23^*	(71.8%)	1^#	(7.7%)	0	0
	nonCitPept	0		1		0

ELISA	CitPept	12^*	(37.5%)	1		0
	nonCitPept	0		1^#		0

Microarray	CitPept	11^*	(34.3%)	0		1^†	(9.1%)
	nonCitPept	3^¥	(9.3%)	0		1^†

P values for anti-CitPept positive RA serum samples by ELISA versus nanotube p = 0.002, ELISA versus microarray p = 0.797, and nanotube versus microarray p = 0.0003.

^¥

Two of the three sera also have reactivity to the citrullinated peptide by ELISA, nanotube and microarray testing.

This is the same NC serum sample that has antibodies to the citrullinated peptide by the nanotube assay, as well as antibodies to the non-citrullinated peptide by ELISA.

^†

This is the same serum sample in the OA group that has antibodies to both the citrullinated and non-citrullinated peptide by microarray testing.